Millie
your market intelligence analyst
Search Results
145 results
Your search is now limited to «Non-Hodgkin Lymphoma» expert search.
BioNewsFeeds 08/23/2019 10:29
Zanubrutinib received fast track designation from the FDA for people with Waldenström macroglobulinemia.
More from BioNewsFeeds:
Healio News 08/22/2019 13:57
The FDA granted priority review of the new drug application based, in part, on data from a global phase 1/phase 2 trial among patients with B-cell lymphomas and a multicenter phase 2 trial among patients with relapsed or refractory mantle cell lymphoma, in addition to safety data on 641 patients from five trials and nonclinical data.
More from Healio News:
GlobeNewswire 08/21/2019 16:30
The NDA data package includes data from the global Phase 1/2 trial (NCT02343120) in patients with B-cell lymphomas and an aggregate of 123 patients in the multicenter Phase 2 trial of zanubrutinib in patients with relapsed or refractory (R/R) MCL in China (NCT03206970), as well as safety data on 641 patients from ...
More from GlobeNewswire:
ClinicalTrials.gov 08/20/2019 08:22
Condition : Mantle Cell Lymphoma Intervention : Sponsor : Samsung Medical Center Active, not recruiting.
More from ClinicalTrials.gov:
Journal of Clinical Oncology, Ahead of Print.
More from American Society of Clinical Oncolgy (ASCO):
Purpose:. The oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase Ib/II study results investigating single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia. Patients and Methods:. The primary objectives were to determine the MTD, safety, and tolerability of oprozomib (phase Ib) as well as overall response rate (ORR; phase II). Oprozomib was administered once daily on days 1, 2, 8, and 9 (2/7 schedule) or days 1 to 5 (5/14 schedule) of a 14-day cycle. Results:. In patients with multiple myeloma or Waldenström macroglobulinemia ( n = 71), the determined MTDs were 300 mg/day (2/7 schedule) and 240 mg/day (5/14 schedule). Median oprozomib treatment durati.
More from Clinical Cancer Research - Recent Issues (abstracts):
PR Newswire 08/12/2019 10:00
Known as limited distribution drugs (LDDs), these specialty medicines treat certain types of multiple sclerosis (MS), Lambert-Eaton myasthenic syndrome (LEMS) and a form of non-Hodgkin's lymphoma (NHL), among other complex conditions.
More from PR Newswire:
PubMed News (NIH) 08/08/2019 21:00
NCI Waldenstrom Macroglobulinemia Genome-wide Association Study. (. |. )
More from PubMed News (NIH):
Medindia.com 08/04/2019 02:25
Compared with individuals without cancer, there was a statistically significant association between BRCA2 mutations and risk of non-Hodgkin lymphoma but not Hodgkin lymphoma.
More from Medindia.com:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications